Cédric M Hysek1, Matthias E Liechti. 1. Division of Clinical Pharmacology and Toxicology, Departments of Biomedicine and Internal Medicine, University Hospital Basel and University of Basel, Hebelstrasse 2, CH-4031 Basel, Switzerland.
Abstract
RATIONALE: Pupillometry can be used to characterize autonomic drug effects. OBJECTIVE: This study was conducted to determine the autonomic effects of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), administered alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin, on pupillary function. METHODS: Infrared pupillometry was performed in five placebo-controlled randomized studies. Each study included 16 healthy subjects (eight men, eight women) who receivedplacebo-MDMA (125 mg), placebo-placebo, pretreatment-placebo, or pretreatment-MDMA using a crossover design. RESULTS:MDMA produced mydriasis, prolonged the latency, reduced the response to light, and shortened the recovery time. The impaired reflex response was associated with subjective, cardiostimulant, and hyperthermic drug effects and returned to normal within 6 h after MDMA administration when plasma MDMA levels were still high. Mydriasis was associated with changes in plasma MDMA concentration over time and longer-lasting. Both reboxetine and duloxetine interacted with the effects of MDMA on pupillary function. Clonidine did not significantly reduce the mydriatic effects of MDMA, although it produced miosis when administered alone. Carvedilol and doxazosin did not alter the effects of MDMA on pupillary function. CONCLUSIONS: The MDMA-induced prolongation of the latency to and reduction of light-induced miosis indicate indirect central parasympathetic inhibition, and the faster recovery time reflects an increased sympathomimetic action. Both norepinephrine and serotonin mediate the effects of MDMA on pupillary function. Although mydriasis is lasting and mirrors the plasma concentration-time curve of MDMA, the impairment in the reaction to light is associated with the subjective and other autonomic effects of MDMA and exhibits acute tolerance.
RCT Entities:
RATIONALE: Pupillometry can be used to characterize autonomic drug effects. OBJECTIVE: This study was conducted to determine the autonomic effects of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), administered alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin, on pupillary function. METHODS: Infrared pupillometry was performed in five placebo-controlled randomized studies. Each study included 16 healthy subjects (eight men, eight women) who received placebo-MDMA (125 mg), placebo-placebo, pretreatment-placebo, or pretreatment-MDMA using a crossover design. RESULTS:MDMA produced mydriasis, prolonged the latency, reduced the response to light, and shortened the recovery time. The impaired reflex response was associated with subjective, cardiostimulant, and hyperthermic drug effects and returned to normal within 6 h after MDMA administration when plasma MDMA levels were still high. Mydriasis was associated with changes in plasma MDMA concentration over time and longer-lasting. Both reboxetine and duloxetine interacted with the effects of MDMA on pupillary function. Clonidine did not significantly reduce the mydriatic effects of MDMA, although it produced miosis when administered alone. Carvedilol and doxazosin did not alter the effects of MDMA on pupillary function. CONCLUSIONS: The MDMA-induced prolongation of the latency to and reduction of light-induced miosis indicate indirect central parasympathetic inhibition, and the faster recovery time reflects an increased sympathomimetic action. Both norepinephrine and serotonin mediate the effects of MDMA on pupillary function. Although mydriasis is lasting and mirrors the plasma concentration-time curve of MDMA, the impairment in the reaction to light is associated with the subjective and other autonomic effects of MDMA and exhibits acute tolerance.
Authors: Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis Journal: J Clin Psychopharmacol Date: 2008-08 Impact factor: 3.153
Authors: Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin Journal: J Psychopharmacol Date: 2010-07-19 Impact factor: 4.153
Authors: Cédric M Hysek; Linda D Simmler; Valentina G Nicola; Nerina Vischer; Massimiliano Donzelli; Stephan Krähenbühl; Eric Grouzmann; Jörg Huwyler; Marius C Hoener; Matthias E Liechti Journal: PLoS One Date: 2012-05-04 Impact factor: 3.240
Authors: Matthew G Kirkpatrick; Matthew J Baggott; John E Mendelson; Gantt P Galloway; Matthias E Liechti; Cédric M Hysek; Harriet de Wit Journal: Psychopharmacology (Berl) Date: 2014-03-15 Impact factor: 4.530
Authors: Matthew G Kirkpatrick; Royce Lee; Margaret C Wardle; Suma Jacob; Harriet de Wit Journal: Neuropsychopharmacology Date: 2014-01-22 Impact factor: 7.853
Authors: Cédric M Hysek; Yasmin Schmid; Linda D Simmler; Gregor Domes; Markus Heinrichs; Christoph Eisenegger; Katrin H Preller; Boris B Quednow; Matthias E Liechti Journal: Soc Cogn Affect Neurosci Date: 2013-10-04 Impact factor: 3.436
Authors: Christine M Clark; Charles G Frye; Margaret C Wardle; Greg J Norman; Harriet de Wit Journal: Psychophysiology Date: 2014-09-11 Impact factor: 4.016
Authors: Matthew G Kirkpatrick; Sunday M Francis; Royce Lee; Harriet de Wit; Suma Jacob Journal: Psychoneuroendocrinology Date: 2014-04-19 Impact factor: 4.905